SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-24-018311
Filing Date
2024-05-09
Accepted
2024-05-09 06:06:19
Documents
68
Period of Report
2024-03-31

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 1026008
2 ex31-1.htm EX-31.1 16625
3 ex31-2.htm EX-31.2 16610
4 ex32-1.htm EX-32.1 5123
5 ex32-2.htm EX-32.2 5156
6 image_001.jpg GRAPHIC 211364
  Complete submission text file 0001493152-24-018311.txt   5661219

Data Files

Seq Description Document Type Size
7 XBRL SCHEMA FILE lpcn-20240331.xsd EX-101.SCH 37326
8 XBRL CALCULATION FILE lpcn-20240331_cal.xml EX-101.CAL 45262
9 XBRL DEFINITION FILE lpcn-20240331_def.xml EX-101.DEF 182813
10 XBRL LABEL FILE lpcn-20240331_lab.xml EX-101.LAB 326775
11 XBRL PRESENTATION FILE lpcn-20240331_pre.xml EX-101.PRE 276993
72 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 707688
Mailing Address 675 ARAPEEN DRIVE, SUITE 202 SALT LAKE CITY X1 84108
Business Address 675 ARAPEEN DRIVE, SUITE 202 SALT LAKE CITY X1 84108 801 994 7383
Lipocine Inc. (Filer) CIK: 0001535955 (see all company filings)

IRS No.: 990370688 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36357 | Film No.: 24928351
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)